医学
药品
肝损伤
药效学
内科学
药代动力学
人口
不利影响
更年期
药理学
环境卫生
作者
Annarosa Floreani,Debora Bizzaro,Sarah Shalaby,Gloria Taliani,Patrizia Burra
标识
DOI:10.1016/j.dld.2022.06.025
摘要
Drug-induced liver injury (DILI) is a potentially serious clinical condition that remains a major problem for patients, physicians and those involved in the development of new drugs. Population and hospital-based studies have reported incidences of DILI varying from 1.4 to 19.1/100.000. Overall, females have a 1.5- to 1.7-fold greater risk of developing adverse drug reactions and the female/male ratio increases after the age of 49 years, suggesting a clear susceptibility of DILI after menopause. Sex differences in pharmacokinetics and pharmacodynamic, sex-specific hormonal effects or interaction with signalling molecules that can influence drug efficacy and safety and differences in abnormal immune response following drug exposure are the main probable causes of the higher vulnerability observed among female patients. A novel phenotype of autoimmune-mediated DILI following the use of check-point inhibitors in oncology and haematology has been recently described. Finally, there have been increasing reports of DILI associated with use of herbal and dietary supplements that is more frequently reported in women.
科研通智能强力驱动
Strongly Powered by AbleSci AI